WuXi XDC provides single-source discovery, development and manufacturing services for antibody drug conjugates (ADCs) and other novel bioconjugates.

Akero Therapeutics is a clinical stage biotechnology company developing novel therapies for patients with non-alcoholic steatohepatitis (NASH).

Acelyrin is a late-stage clinical biotech company focused on acquiring and accelerating the development of immunology medicines.

Karuna Therapeutics is a clinical-stage biotechnology company developing a novel oral drug for schizophrenia and Alzheimer's Disease related psychosis.

LePure is a provider of single-use bioprocess solutions for biopharmaceutical companies in China.

Javara is an integrated research organization that partners with healthcare providers to bring clinical trial capabilities to established points-of-care (“clinical-research-as-a-care-option”, or “CRAACO”).

WuXi Biologics a contract development and manufacturing organization that provides outsourcing services for pharmaceutical and biotechnology companies in all stages of the biologics development process.

Solve Therapeutics is a biopharmaceutical company that develops next-generation antibody-drug conjugates and bispecific therapeutics for cancer.

Third Harmonic Bio is a clinical stage biotechnology company developing an oral KIT inhibitor therapy for allergic autoimmune disorders.

Ultima Genomics focuses on developing next-generation genome sequencing technology for the high-volume research and clinical markets.

CinCor Pharma is a clinical-stage biopharmaceutical company with a mission to bring innovation to the treatment of hypertension.

Genesis MedTech is a leading medical technology and device platform focused on the emerging markets.

Biotheus is a clinical development stage company treating cancer and autoimmune diseases through next-generation therapeutics.

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process, with a subsidiary portfolio supported by a centralized infrastructure, asset-centric R&D model and the Centessa management team.

Kalbe Genexine Biologics (“KGBio”) is an Indonesia-based joint venture between Kalbe Farma and Genexine. KGBio focuses on the in-licensing, clinical development, and manufacturing of biological products, especially in the area of immuno-oncology.

Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition.